文献速递白血病

继发性与原发性急性髓系白血病的预后影响可由欧洲白血病网2022风险分类解释

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
PubMed 文献 · Leukemia · 2023-07-31

该多中心队列研究纳入734例急性髓系白血病患者,分析继发性(有前驱血液病史或既往基因毒性治疗)与原发性疾病的预后差异,发现校正遗传学特征后异常血细胞计数无独立预后意义,前驱血液病史和治疗相关AML在多变量分析中不增加死亡风险,提示起源的预后影响可由ELN 2022风险和TP53突变状态解释。

要点

  • 异常血细胞计数在原发性AML中校正遗传学特征后无独立预后意义。
  • 前驱血液病史和治疗相关AML在多变量分析中不增加死亡风险。
  • 疾病遗传学应在AML风险分层和临床试验入组中起重要作用。

核心结论

  • 继发性AML的预后影响可由ELN 2022风险分类和TP53突变状态所解释。

研究设计与样本

  • 大型多中心队列研究,纳入734例急性髓系白血病患者。

主要发现

  • 在原发性AML患者中,异常血细胞计数校正遗传学特征后无独立预后意义。
  • 前驱血液病史和治疗相关AML在多变量分析中与原发性AML相比不增加死亡风险。

临床怎么用

  • 作者强调疾病遗传学应在AML风险分层和临床试验入组中起重要作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary AML (sAML), defined by either history of antecedent hematologic disease (AHD) or prior genotoxic therapy (tAML), is classically regarded as having worse prognosis than de novo disease (dnAML). Clinicians may infer a new AML diagnosis is secondary based on a history of antecedent blood count (ABC) abnormalities in the absence of known prior AHD, but whether abnormal ABCs are associated with worse outcomes is unclear. Secondary-type mutations have recently been incorporated into the European LeukemiaNet (ELN) 2022 guidelines as adverse-risk features, raising the question of whether clinical descriptors of ontogeny (i.e., de novo or secondary) are prognostically significant when accounting for genetic risk by ELN 2022. In a large multicenter cohort of patients (n = 734), we found that abnormal ABCs are not independently prognostic after adjusting for genetic characteristics in dnAML patients. Furthermore, history of AHD and tAML do not confer increased risk of death compared to dnAML on multivariate analysis, suggesting the prognostic impact of ontogeny is accounted for by disease genetics as stratified by ELN 2022 risk and TP53 mutation status. These findings emphasize the importance that disease genetics should play in risk stratification and clinical trial eligibility in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hochman MJ, Othus M, Hasserjian RP, et al. Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification. Leukemia. 2023. PMID: 37524919. doi:10.1038/s41375-023-01985-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。